Kaposiform Hemangioendothelioma Clinical Trial
Official title:
Efficacy and Safety of Usual- vs Low-Dose Sirolimus in Patients With Kaposiform Hemangioendothelioma: A Trial Protocol
The purpose of this study is to compare the efficacy and safety of different concentration gradients of sirolimus in the treatment of Kaposiform hemangioendothelioma.
Kaposiform hemangioendothelioma (KHE) is a rare aggressive vascular neoplasm that occurs predominantly in infancy or early childhood, with an incidence of approximately 0.71/100,000. Currently, sirolimus is a promising treatment modality for KHE. Most scholars consider sirolimus blood concentration of 5-15 ng/ml to be an effective therapeutic concentration. However, long-term higher dose sirolimus treatment can cause some common complications such as oral mucositis which affects the quality of life of the patient. Finer control of the plasma concentration of sirolimus may contribute to the efficacy of treatment and reduce the incidence of complications. Therefore, we conducted this study to see if low-dose sirolimus is beneficial to the prognosis of patients. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04921722 -
Percutaneous Administration of Sirolimus in the Treatment of Superficial Complicated Vascular Anomalies
|
Phase 4 | |
| Completed |
NCT04077515 -
Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma
|
Phase 4 | |
| Recruiting |
NCT05351216 -
The Effect of Sirolimus on Immunizations During the Treatment of Kaposiform Hemangioendothelioma
|
||
| Completed |
NCT03188068 -
Sirolimus Versus Sirolimus Plus Prednisolone for Kaposiform Hemangioendothelioma
|
Phase 2 | |
| Completed |
NCT04448873 -
Guided Discontinuation Versus Maintenance Treatment of Sirolimus in Pediatric Patients With Kaposiform Hemangioendothelioma
|
Phase 4 | |
| Recruiting |
NCT03001180 -
Identification of Biomarkers for Patients With Vascular Anomalies
|